Doximity, Inc.
At today's price, Doximity, Inc. (DOCS) is priced for +17.7% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
Doximity is the largest professional network for US physicians, with roughly 85% of doctors registered, and it monetizes that reach mainly through pharmaceutical marketing. Operating margin runs about 33% and the company is debt-free with about $749 million of cash. At about $20 the price inverts to roughly 15% operating-profit growth a year, which the relative-multiple and growth-DCF methods support while the asset and earnings-power frames call it expensive. The stock has fallen as margins c
Is DOCS overvalued? See what's priced in →
405 institutional managers reported holding DOCS in 13F filings for the quarter ended 2026-03-31. Together they hold about 60% of the company; the top 10 hold 29%. 68 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 18.8M shares were sold short as of the 2026-06-15 count, about 9% of shares outstanding (5.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
DOCS's share count grew 114% over the past five years even with $917.99M spent on repurchases. It pays no dividend. Cash returned over the past three years: $810.91M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at DOCS over the trailing three years. Absence is a fact about the company, not a signal. 8 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
DOCS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | -26.6% | -12.0% |
| 2023-11-10 | +13.1% | +24.0% |
| 2024-02-09 | +4.3% | -9.5% |
| 2024-05-24 | +17.5% | +1.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
DOCS's latest 8-K filings: 2026-05-13 (items 2.02, 5.02, 9.01); 2026-04-17 (items 5.02, 7.01); 2026-02-05 (items 2.02, 5.02, 9.01); 2025-12-30 (items 8.01); 2025-11-06 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.